Quote Request
Syngeneic Mouse Models for Pancreatic Cancer
The syngeneic mouse model effectively studies how pancreatic cancer therapies work in the presence of a functional immune system. Alfa Cytology is a leading preclinical research service provider. We have extensive experience constructing syngeneic models for pancreatic cancer (PC).
Overview of Syngeneic Models
The difference between the syngeneic mouse model, also known as the allogeneic mouse tumor system, and the humanized mouse model is the source of the cancer being monitored. In the humanized mouse model, the cancer cells were taken directly from humans, while in the syngeneic mouse model, the cancer cells came from mice or genetically similar rodents. Genetically identical mouse models are generated through a transplant or grafting procedure, in which one mouse's cells, tissues, or organs are transplanted into another mouse.
Fig. 1 To establish a syngeneic mouse model for evaluating immunotherapy. (Chulpanova, D.S., et al., 2020)
Syngeneic transplantation is less prone to rejection and less dependent on immunosuppressive drugs. Syngeneic mouse models are used in cancer research to determine the overall efficacy of novel therapies. Tumor growth is monitored in the context of different therapies, thus providing clues to how various therapies affect tumor growth.
Our Services
Alfa Cytology offers a variety of syngeneic mouse models, including those that respond to immunotherapy. Because genetically identical mice retain intact immune systems, they are particularly suitable for immunotherapy research. Examples of uses include cancer therapies targeting immune checkpoints or immunostimulatory molecules.
Syngeneic Mouse Models for Immunotherapy
Alfa Cytology provides immunoassays and genetically evaluated syngeneic mouse models, such as Pan02, with a clear response to known immune checkpoint inhibitors.
- Anti-PDL-1
- Anti-PD-1
- Anti-CTLA-4
Applications of the syngeneic model include but are not limited to the following.
- Responsiveness to known immunomodulatory therapies
- Extent and composition of tumor-infiltrating lymphocytes (TILs)
- Immunogenicity testing
Syngeneic Mouse Model Strains
We offer syngeneic mouse models with and without profiles. The following syngeneic models are available.
- CD1
- Swiss Nude
- B6
- NSG
- Balb/c
- CB17
- Balb/SCID
- CD57BL
- NOD/SCID
- Nu/nu
In addition to a wide range of mouse models, Alfa Cytology offers comprehensive pharmacodynamics, toxicology evaluation, and pharmacokinetics services in the syngeneic model.
Why Choose Us?
Scientific Experience
Professional team of scientists and more than ten years of experience in pancreatic cancer
Customized Service
Tailored services dedicated to ensuring customer satisfaction
Data Security
Strictly keep confidential the client's project information and experimental data
Quick Reply
Our customer service representatives are available 24 hours a day from Monday to Sunday
Case Study - Panc02 Syngeneic Model
- Model Introduction
The Panc02 syngeneic cell line serves as a fundamental tool for pancreatic cancer immunology research. It was derived from a grade Ⅲ pancreatic adenocarcinoma induced by 3-methylcholanthrene (3-MCA) in male C57BL/6 mice. This model maintains a fully intact and functional host immune system, making it an ideal platform for investigating tumor-immune interactions and evaluating immunotherapeutic strategies.
- Model Information
- Model: Panc02 Syngeneic Model
- Animals: C57BL/6 Mice
- Age: 6-8 Weeks
- Cancer Type: Adenocarcinoma
- Weight: 18-22 g
- Model Construction
A suspension of Panc02 cells (typically 0.5-1×106 cells in 100 µL of Matrigel mixture) is inoculated subcutaneously into the flank of immunocompetent C57BL/6 mice aged 6-8 weeks. After tumor inoculation, animals are monitored until tumors reach a target volume (typically 50-100 mm3), establishing a reliable baseline for subsequent therapeutic intervention.
Fig. 2 Workflow of Panc02 syngeneic model establishment. (Source: Alfa Cytology)
- Model Data
- Tumor Growth Kinetics: Panc02 tumors exhibit relatively slow but consistent growth when implanted subcutaneously in C57BL/6 mice, providing an extended therapeutic window for intervention studies. The tumors display a distinctive invasive growth pattern, frequently infiltrating the adjacent muscle layer and forming flat, plaque-like masses rather than well-defined spherical nodules.
- Response Profile to Immunotherapy: The Panc02 syngeneic model demonstrates characteristic resistance to single-agent immune checkpoint inhibitor therapy, showing weak response to anti-PD-1 monotherapies.
Fig. 3 Panc02 syngeneic tumor growth, body weight, and anti-PD-1 response in C57BL/6 mice. (A) Tumor growth curve of subcutaneous Panc02 allografts. (B) Body weight changes in tumor-bearing mice (n=6). (C) Anti-tumor activity following anti-PD-1 treatment (n=6). Data are expressed as mean ± SEM. (Source: Alfa Cytology)
With syngeneic models that respond to immunotherapy, patient-derived xenotransplantation (PDX) models, humanized models, and preclinical validation platforms, Alfa Cytology is the ideal partner to advance your immuno-oncology pipeline. Based on our comprehensive expertise in pancreatic cancer and advanced technology platform, we can develop various PC syngeneic models for our customers for research and preclinical purposes. If you are interested in our services, please contact us for more details. You can contact our staff directly and receive professional, reliable, and fast feedback.
Reference
- Chulpanova, D.S.; et al. Mouse Tumor Models for Advanced Cancer Immunotherapy. Int. J. Mol. Sci. 2020, 21, 4118. https://doi.org/10.3390/ijms21114118
